Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins

• US 10,689,640 B2
• Filed: 12/19/2016
• Issued: 06/23/2020
• Est. Priority Date: 04/27/2007
• Status: Active Grant

• Current Assignee: Pelican Technology Holdings, Inc (Primordial Genetics Inc.)
• Original Assignee: Pfenex Inc.
• Inventors: Retallack, Diane M., Squires, Charles H., Ramseier, Thomas M., Coleman, Russell J., Schneider, Jane C., Hershberger, Charles D.
• Primary Examiner(s): Brown, Mindy G
• Application Number:
  US15/384,029
• Publication Number:
  US 20170183646A1
• Time in Patent Office: 1,282 Days
• Field of Search: None
• CPC Class Codes: C12N 15/1037 Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
• CPC Class Codes: C12N 15/78 for Pseudomonas

Abstract

The present invention provides an array for rapidly identifying a host cell population capable of producing a heterologous recombinant protein with improved yield and/or quality. The array comprises one or more host cell populations that have been genetically modified to increase the expression of one or more target genes involved in protein production, decrease the expression of one or more target genes involved in protein degradation, or both. One or more of the strains in the array may express the heterologous recombinant protein of interest in a periplasm compartment or may secrete the heterologous recombinant protein extracellularly through an outer cell wall. The strain arrays are useful for screening for improved expression of any protein of interest including therapeutic proteins, hormones, growth factors, extracellular receptors or ligands, proteases, kinases, blood proteins, chemokines, cytokines, antibodies and the like.

Claims

1. A method for selecting at least one optimal expression system for use in the expression of at least one heterologous recombinant protein, the method comprising:

a. obtaining an array assembled using a method comprising;

placing in separate addressable locations on the array at least 10 nonidentical test expression systems, said at least 10 nonidentical test expression systems each comprising a different combination of

i. a Pseudomonad or E. coli host cell population, and

ii. at least one expression vector encoding the at least one heterologous recombinant protein,

wherein the array includes at least 5 different host cell populations and at least 2 different expression vectors, and further wherein at least 3 of said at least 5 different host cell populations are deficient in their expression of at least one protease;

b. simultaneously screening the at least 10 nonidentical test expression systems on the array, wherein at least one of the nonidentical test expression systems overexpresses the heterologous recombinant protein as compared to an indicator strain; and

c. selecting at least one optimal expression system based on improved expression of each at least one heterologous recombinant protein in the optimal expression system.

2. The method of claim 1, wherein the improved expression of the heterologous recombinant protein by the selected optimal expression system is an increase in yield of the heterologous recombinant protein, of about 1.5-fold to about 100-fold, relative to the yield in an indicator expression system.

3. The method of claim 1 wherein the improved expression of the heterologous recombinant protein is a yield of the heterologous recombinant protein by the selected optimal expression system of about 10 mg/liter to about 2000 mg/liter.

4. The method of claim 1 wherein the improved expression is a yield of the heterologous recombinant protein by the selected optimal expression system of about 0.1 mg/ml to about 50 mg/ml, wherein the heterologous recombinant protein is correctly processed protein.

5. The method of claim 2 wherein the indicator expression system comprises a second expression system in the array of the at least 10 nonidentical test expression systems in the array, or a standard expression system.

6. The method of claim 2, wherein the yield of the heterologous recombinant protein is a measure of one or more of:

the amount of soluble heterologous recombinant protein, the amount of recoverable heterologous recombinant protein, the amount of properly processed heterologous recombinant protein, the amount of properly folded heterologous recombinant protein, the amount of active heterologous recombinant protein, and the total amount of heterologous recombinant protein.

7. The method of claim 1, wherein the at least 2 different expression vectors each encode a different heterologous recombinant protein.

8. The method of claim 7, wherein the array includes at least 5 different expression vectors, and wherein each of said at least 5 different expression vectors encodes a different heterologous recombinant protein.

9. The method of claim 1, wherein at least one expression vector encodes 2 different heterologous recombinant proteins.

10. The method of claim 1, wherein at least 20 nonidentical test expression systems are placed in separate addressable locations, and wherein the array includes at least 10 different host cell populations and at least 2 different expression vectors, and further wherein at least 5 of said at least 10 different host cell populations are deficient in their expression of at least one protease.

11. The method of claim 1, wherein at least 50 nonidentical test expression systems are placed in separate addressable locations, and wherein the array includes at least 20 different host cell populations and at least 3 different expression vectors, and further wherein at least 10 of said at least 20 different host cell populations are deficient in their expression of at least one protease.

12. The method of claim 1, wherein at least 2 of said at least 5 different host cell populations overexpress at least one folding modulator.

13. The method of claim 12, wherein the at least one folding modulator is encoded by a nucleic acid sequence selected from the group consisting of:

SEQ ID NO;

3, SEQ ID NO;

4, SEQ ID NO;

5, SEQ ID NO;

6, SEQ ID NO;

7, SEQ ID NO;

8, SEQ ID NO;

9, SEQ ID NO;

10, SEQ ID NO;

11, SEQ ID NO;

12, SEQ ID NO;

13, SEQ ID NO;

14, SEQ ID NO;

1, SEQ ID NO;

16, SEQ ID NO;

17, SEQ ID NO;

18, SEQ ID NO;

19, SEQ ID NO;

20, SEQ ID NO;

21, SEQ ID NO;

22, SEQ ID NO;

23, SEQ ID NO;

24, SEQ ID NO;

25, SEQ ID NO;

26, SEQ ID NO;

27, SEQ ID NO;

28, SEQ ID NO;

29, SEQ ID NO;

30, SEQ ID NO;

31, SEQ ID NO;

32, SEQ ID NO;

33, SEQ ID NO;

34, SEQ ID NO;

35, SEQ ID NO;

36, SEQ ID NO;

37, SEQ ID NO;

38, SEQ ID NO;

39, SEQ ID NO;

40, SEQ ID NO;

41, SEQ ID NO;

42, SEQ ID NO;

43, SEQ ID NO;

44, SEQ ID NO;

45, SEQ ID NO;

137, SEQ ID NO;

138, SEQ ID NO;

139, SEQ ID NO;

140, SEQ ID NO;

141, SEQ ID NO;

142, SEQ ID NO;

143, SEQ ID NO;

144, SEQ ID NO;

145, SEQ ID NO;

146, SEQ ID NO;

147, SEQ ID NO;

148, SEQ ID NO;

149, and SEQ ID NO;

150.

14. The method of claim 12, wherein the at least one folding modulator is expressed from a plasmid.

15. The method of claim 1, wherein at least one host cell population in the array is defective in at least one to about eight host cell proteases.

16. The method of claim 15, wherein the at least one to about eight host cell proteases are selected from the proteases encoded by a nucleic acid sequence selected from the group consisting of:

SEQ ID NO;

110, SEQ ID NO;

109, SEQ ID NO;

69, SEQ ID NO;

66, SEQ ID NO;

100, SEQ ID NO;

101, SEQ ID NO;

61, SEQ ID NO;

130, SEQ ID NO;

52, SEQ ID NO;

91, SEQ ID NO;

106, SEQ ID NO;

111, SEQ ID NO;

86, SEQ ID NO;

89, SEQ ID NO;

60, SEQ ID NO;

88, SEQ ID NO;

74, SEQ ID NO;

132, SEQ ID NO;

80, SEQ ID NO;

63, SEQ ID NO;

64, SEQ ID NO;

82, SEQ ID NO;

47, SEQ ID NO;

125, SEQ ID NO;

54, SEQ ID NO;

85, SEQ ID NO;

62, SEQ ID NO;

81, SEQ ID NO;

112, SEQ ID NO;

113, SEQ ID NO;

76, SEQ ID NO;

58, SEQ ID NO;

83, SEQ ID NO;

133, SEQ ID NO;

96, SEQ ID NO;

78, SEQ ID NO;

75, SEQ ID NO;

119, SEQ ID NO;

107, SEQ ID NO;

105, SEQ ID NO;

95, SEQ ID NO;

57, SEQ ID NO;

124, SEQ ID NO;

121, SEQ ID NO;

127, SEQ ID NO;

128, SEQ ID NO;

115, SEQ ID NO;

131, SEQ ID NO;

118, SEQ ID NO;

67, SEQ ID NO;

51, SEQ ID NO;

93, SEQ ID NO;

2, SEQ ID NO;

46, SEQ ID NO;

102, SEQ ID NO;

90, SEQ ID NO;

94, SEQ ID NO;

92, SEQ ID NO;

129, SEQ ID NO;

114, SEQ ID NO;

50, SEQ ID NO;

79, SEQ ID NO;

56, SEQ ID NO;

108, SEQ ID NO;

98, SEQ ID NO;

99, SEQ ID NO;

120, SEQ ID NO;

55, SEQ ID NO;

123, SEQ ID NO;

117, SEQ ID NO;

122, SEQ ID NO;

59, SEQ ID NO;

116, SEQ ID NO;

19, SEQ ID NO;

70, SEQ ID NO;

87, SEQ ID NO;

49, SEQ ID NO;

68, SEQ ID NO;

97, SEQ ID NO;

104, SEQ ID NO;

103, SEQ ID NO;

48, SEQ ID NO;

72, SEQ ID NO;

73, SEQ ID NO;

77, SEQ ID NO;

71, SEQ ID NO;

84, SEQ ID NO;

126, SEQ ID NO;

134, SEQ ID NO;

135, SEQ ID NO;

136, SEQ ID NO;

151, SEQ ID NO;

152, SEQ ID NO;

153, SEQ ID NO;

154, SEQ ID NO;

155, SEQ ID NO;

156, and SEQ ID NO;

157.

17. The method of claim 1, further comprising determining the number of cysteine residues in, the presence of clustered prolines in, the requirement of an N-terminal methionine for activity of, or the presence of a small amino acid in the plus two position of, the heterologous recombinant protein.

18. The method of claim 17, wherein when the heterologous recombinant protein has more than two cysteine residues, at least one of said at least 2 different expression systems overexpressing a folding modulator overexpresses a disulfide isomerase/oxidoreductase.

19. The method of claim 18, wherein the disulfide isomerase/oxidoreductase is encoded on a plasmid.

20. The method of claim 17, wherein when the heterologous recombinant protein has more than four cysteine residues, at least one of said at least 2 different expression vectors encoding the heterologous recombinant protein contains a periplasmic secretion leader coding sequence.

21. The method of claim 17, wherein when the heterologous recombinant protein has more than four cysteine residues, at least one of said at least 2 different expression vectors encoding the heterologous recombinant protein contains a high or medium ribosome binding sequence.

22. The method of claim 20, further wherein said at least one of said at least 2 different expression vectors encoding the heterologous recombinant protein and containing a periplasmic secretion leader coding sequence is included in at least one expression system that overexpresses at least one periplasmic chaperone, and at least one expression system that overexpresses at least one cytoplasmic chaperone.

23. The method of claim 17, wherein when the heterologous recombinant protein has fewer than four cysteine residues, at least one of said at least 2 different expression vectors encoding the heterologous recombinant protein does not contain a periplasmic secretion leader coding sequence, and further wherein said at least one of said at least 2 different expression vectors encoding the heterologous recombinant protein and not containing a periplasmic secretion leader coding sequence is included in at least one expression system that overexpresses at least one cytoplasmic chaperone.

24. The method of claim 17, wherein when clustered prolines are present, at least one expression system that overexpresses at least one 2+ peptidyl-prolyl cis-trans isomerase (PPIase) is included in the array.

25. The method of claim 24, wherein the 2+ peptidyl-prolyl cis-trans isomerase (PPIase) is encoded on a plasmid.

26. The method of claim 17, wherein when the N-terminal methionine is required, at least one expression system comprising a host cell population that has at least one defect in at least one host cell methionyl amino peptidase, is included in the array.

27. The method of claim 17, wherein when a small amino acid is present in the plus two position of the heterologous recombinant protein, at least one expression system comprising a host cell population that has at least one defect in at least one amino peptidase, is included in the array.

28. The method of claim 17, wherein the small amino acid is selected from the group consisting of:

glycine, alanine, valine, serine, threonine, aspartic acid, asparagine, and proline.

29. The method of claim 1, wherein the heterologous recombinant protein is selected from the group consisting of:

a toxin;

a cytokine, growth factor or hormone, or receptor thereof;

an antibody or antibody derivative;

a human therapeutic protein or therapeutic enzyme;

a non-natural protein or a fusion protein;

a chaperone;

a pathogen protein or pathogen-derived antigen;

a lipoprotein;

a reagent protein; and

a biocatalytic enzyme.

30. The method of claim 29, wherein the toxin is a vertebrate or invertebrate animal toxin, a plant toxin, a bacterial toxin, a fungal toxin, or variant thereof.

31. The method of claim 29, wherein the antibody or antibody derivative is a humanized antibody, modified antibody, nanobody, bispecific antibody, single-chain antibody, Fab, Domain antibody, shark single domain antibody, camelid single domain antibody, linear antibody, diabody, or BiTE molecule.

32. The method of claim 1, wherein at least 10% of the heterologous recombinant protein is insoluble when expressed in the indicator strain, or wherein the heterologous recombinant protein is predicted to be insoluble using a protein solubility prediction tool.

33. The method of claim 3, wherein the yield of the heterologous recombinant protein is a measure of one or more of:

the amount of soluble heterologous recombinant protein, the amount of recoverable heterologous recombinant protein, the amount of properly processed heterologous recombinant protein, the amount of properly folded heterologous recombinant protein, the amount of active heterologous recombinant protein, and the total amount of heterologous recombinant protein.

34. The method of claim 1, wherein at least one of said at least 2 different expression vectors encodes a periplasmic secretion leader sequence operably linked to the heterologous recombinant protein.

35. The method of claim 1, wherein the improved expression is a yield of the heterologous recombinant protein of about 10 mg/ml to about 25 mg/ml in the periplasmic compartment of the host cell of the at least one nonidentical test expression system.